TLSA — Tiziana Life Sciences Ltd
6 mentions in the last 24 hours · 0.04% of all mentions
Why people talked about TLSA (2026-11-03)
- Tiziana Life Sciences reported positive Phase 2a results for its intranasal drug Foralumab in treating Multiple Sclerosis.
- The company highlighted data showing reduced brain inflammation and improvements in fatigue and imaging metrics.
- Despite the positive clinical milestones, the stock price experienced a decline following the announcement.
| GDELT | 5 | news |
| RSS Bundle | 1 | news |